Patents Assigned to ORIC PHARMACEUTICALS, INC.
-
Patent number: 11858915Abstract: Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 27, 2023Date of Patent: January 2, 2024Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Chudi Ndubaku, Jared Thomas Moore, Paul Anthony Gibbons, Jae Hyuk Chang, F. Anthony Romero, Xiaohui Du, Hiroyuki Kawai, Stephane Ciblat, Hong Wang, Vincent Albert, Lea Constantineau-Forget, Hugo De Almeida Silva, Dilan Emine Polat, Amit Nayyar, Daniel Gordon Michael Shore, Kejia Wu, Joanne Tan
-
Patent number: 11807658Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.Type: GrantFiled: March 17, 2022Date of Patent: November 7, 2023Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai
-
Patent number: 11576922Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.Type: GrantFiled: August 17, 2021Date of Patent: February 14, 2023Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Erica L. Jackson, Daqing Sun, Qiuping Ye, Jared Moore
-
Patent number: 11530236Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.Type: GrantFiled: October 29, 2020Date of Patent: December 20, 2022Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai, Chien-Hung Yeh
-
Patent number: 11377469Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.Type: GrantFiled: November 2, 2018Date of Patent: July 5, 2022Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Erica L. Jackson, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya
-
Patent number: 11325938Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.Type: GrantFiled: October 23, 2020Date of Patent: May 10, 2022Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai
-
Patent number: 11208432Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.Type: GrantFiled: December 22, 2016Date of Patent: December 28, 2021Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Haiying Zhou, Minna Delarae Balbas, Valeria R. Fantin
-
Patent number: 11130778Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.Type: GrantFiled: March 17, 2021Date of Patent: September 28, 2021Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai, Chien-Hung Yeh
-
Patent number: 11129841Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.Type: GrantFiled: May 9, 2018Date of Patent: September 28, 2021Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Erica L. Jackson, Daqing Sun, Qiuping Ye, Jared Moore
-
Patent number: 11124537Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.Type: GrantFiled: December 22, 2016Date of Patent: September 21, 2021Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Haiying Zhou, Minna Delarae Balbas, Valeria R. Fantin
-
Patent number: 11110103Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.Type: GrantFiled: December 22, 2016Date of Patent: September 7, 2021Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Haiying Zhou, Minna Delarae Balbas, Valeria R. Fantin
-
Patent number: 11028120Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.Type: GrantFiled: December 8, 2020Date of Patent: June 8, 2021Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai, Chien-Hung Yeh
-
Patent number: 10836789Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.Type: GrantFiled: June 1, 2020Date of Patent: November 17, 2020Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Valeria R. Fantin, Haiying Zhou, Minna Delarae Balbas
-
Patent number: 10723759Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.Type: GrantFiled: September 5, 2019Date of Patent: July 28, 2020Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Valeria R. Fantin, Haiying Zhou, Minna Delarae Balbas
-
Patent number: 10472387Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.Type: GrantFiled: March 26, 2019Date of Patent: November 12, 2019Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina